First Trust Nasdaq Pharmaceuticals ETF
FTXH
22 hedge funds and large institutions have $8.87M invested in First Trust Nasdaq Pharmaceuticals ETF in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
16% more funds holding
Funds holding: 19 → 22 (+3)
2.13% less ownership
Funds ownership: 49.69% → 47.56% (-2.1%)
13% less capital invested
Capital invested by funds: $10.2M → $8.87M (-$1.29M)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$673K |
| 2 |
GT
Glenview Trust
Louisville,
Kentucky
|
+$582K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$490K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$201K |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$2.98M |
| 2 |
KNW
Kesler Norman & Wride
Ogden,
Utah
|
-$703K |
| 3 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
-$206K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$186K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$50.7K |
FTXH Hedge Fund Activity: Q4 2023 in Review
22 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q4 2023, worth a combined $8.87M — down 13% from $10.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new FTXH positions and 5 closed out — a net gain of 3 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $673K. The largest seller was Raymond James Financial Services Advisors, exiting entirely with an estimated $2.98M sold.
- 22 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q4 2023, up from 19 in Q3 2023.
- Funds reported $8.87M of First Trust Nasdaq Pharmaceuticals ETF stock for Q4 2023, down 13% quarter-over-quarter.
- 8 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q4 2023 and 5 closed out, a net change of +3 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q4 2023 was Goldman Sachs, an estimated $673K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q4 2023 was Raymond James Financial Services Advisors, an estimated $2.98M sold.
Based on aggregated 13F filings for Q4 2023.